Australia

Dashboard Indicators

  • Long-term Control of Eczema Symptoms

    Scores are based on responses to the AD Control Tool: https://www.adcontroltool.com/adct-how-to-use/adct-in-clinical-practice

    Data source: GPIIEC global survey of 3,253 patients and caregivers, 2022.

  • Satisfaction with Eczema Treatments

    Self reported satisfaction with current treatments (caregivers and adults).

    Data source: GPIIEC global survey of 3,253 patients and caregivers, 2022.

  • Life Span Trade-Off (Health Utility)

    Percent of remaining life span adult patients would trade off in order to be restored to perfect health. (Derived from EQ5D Utility Scores)

    Data source: GPIIEC global survey of 3,253 patients and caregivers, 2022.

  • Eczema Patients Self Reported Health to Compared to Country Average

    Self-rated quality of life score for the average person compared to the self-rated quality of life score for adults with eczema. Derived from the EQ5D survey.

    Data source: GPIIEC global survey of 3,253 patients and caregivers, 2022.

  • Dimensions of Health – Relative Impact (Adults)

    Data source: GPIIEC survey of 3,253 patients and caregivers, 2022.

  • Financial Burden – Impacts

    Percent of respondents (adults and caregivers) who reported using savings, borrowing money and/or reducing spending due to eczema. Higher = More Financial Impact.

    Data source: GPIIEC global survey of 3,253 patients and caregivers, 2022.

  • Shared Decision Making

    The percentage of respondents who indicated that the healthcare provider whom they see for eczema asked about their priorities for their eczema care at the most recent visit.

    Data source: GPIIEC global survey of 3,253 patients and caregivers, 2022.

  • Eczema Education and Training

    Respondents who said a health care provider had ever suggested they attend an eczema training program that happens after the office visit.

    Data source: GPIIEC global survey of 3,253 patients and caregivers, 2022.

  • Access to Dermatologists

    Australia ranked 8th out of the 10 countries in access to dermatologists.

    Source: ACD Annual Report 2019 , Australasian College of Dermatologists , 2019.

  • Evidence-Based Guidelines

    The most recent guidelines for Australia (2019) met most criteria for a high-quality guideline but fell short in the area of including a patient advocate, patient or caregiver in the guideline development process.

    Scoring criteria for the guideline measure >

    Source: Smith, Saxon, et al. “Atopic Dermatitis in Adults: An Australian Management Consensus.” Australasian Journal of Dermatology, vol. 61, no. 1, Wiley, Aug. 2019, pp. 23–32.

Literature Review Key Findings

 

Multiple studies noted that the prevalence of AD appears to be increasing in Australian children with AD, but trends among Australian adults are less studied. Additionally, there are few large-scale studies of comorbidities; the existing studies are smaller and interview-based. These findings provide a reasonable starting point, but population-wide studies may give a better picture of the scope of the burden of AD in Australia and may also reveal yet unknown associations. 

Unmet treatment needs were most common among Australian patients with moderate-to-severe AD. As in other countries, part of the problem is rooted in the underutilization of topical corticosteroids, which stems from both inconsistent prescribing practices and fears among patients and caregivers. Small interventions demonstrated preliminary success on both fronts, but much more work is needed in Australia to achieve a coherent approach to treatment.

Learn more about the findings gathered from the Australia literature review.